Abstract Oncogenic KRAS mutations occur in approximately 40% of colorectal cancer (CRC) cases and correlate with poor prognosis. While restoring GTP hydrolysis in KRAS-mutant tumors represents a promising therapeutic strategy, its mechanistic basis remains unclear. KRASQ25A mutant exhibits enhanced intrinsic GTPase activity, but its cellular impact is unknown. Here, we investigated the tumor-suppressive effects of KRASQ25A in KRASG12D-mutant CRC.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Juncheng
Contact Juncheng, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack